<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764659</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00052534</org_study_id>
    <nct_id>NCT01764659</nct_id>
  </id_info>
  <brief_title>4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation</brief_title>
  <acronym>GCC 1210</acronym>
  <official_title>Individually Optimized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to study the feasibility and efficacy of individually optimized CE
      4D-CT for PDA in radiotherapy simulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared with current clinical practice, the individually optimized CE 4D-CT can potentially
      provide much improved tumor-to-parenchyma conspicuity of pancreatic adenocarcinoma. This will
      help the radiation oncologists or radiologists to contour the tumor with higher precision and
      confidence, and compute the tumor volume and tumor motion more accurately.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation</measure>
    <time_frame>1 year</time_frame>
    <description>Image quality (anatomic details, motion artifacts, beam hardening and enhancement of pancreatic tissue and tumor were scored from 1 to 5, with 1 being very poor and 5 being excellent), CT number of pancreas and tumor, tumor-to-pancreas contrast, image noise and contrast-to-noise ration (CNR) were compared among contrast-enhanced (CE) 4DCT, CE 3DCT and 4DCT without contrast enhancement.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>All enrolled patients</arm_group_label>
    <description>Contrast-enhanced 4D computed tomography</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast-enhanced 4D computed tomography</intervention_name>
    <description>All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.</description>
    <arm_group_label>All enrolled patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        GI/GU multi-d clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years old or older

          2. Patients with PDA who have not had surgical removal of their tumor and who are planned
             for treatment with radiotherapy in the Radiation Oncology Department at the University
             of Maryland.

          3. Patients who have signed the contrast consent form and have been recommended by
             physicians to have contrast-enhanced CT scans.

          4. Patients who have signed the consent form for this study

        Exclusion Criteria:

          1. Pregnant or breast-feeding women.

          2. Patients with severely decreased renal function19-21.

          3. Patients with known severe allergic reactions to contrast.

          4. Patients who have difficulty lying flat on their back for extended periods of time.

          5. Patients with breaths per minute (BPM) rate less than 10, due to the limitation of
             4D-CT image reconstruction software.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Lu, Ph. D., DABR</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMMC MSGCC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hao H Zhang, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ummc Msgcc</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 2, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <results_first_submitted>August 22, 2017</results_first_submitted>
  <results_first_submitted_qc>March 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2020</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Department of Radiation Oncology</investigator_full_name>
    <investigator_title>Assistant Professor, Physics</investigator_title>
  </responsible_party>
  <keyword>4D-CT</keyword>
  <keyword>Contrast Enhanced CT</keyword>
  <keyword>Radiotherapy Simulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Enrolled Patients</title>
          <description>Individually optimized CE 4D-CT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GI Group</title>
          <description>Study the feasibility and efficacy of individually optimized CE 4D-CT for PDA in radiotherapy simulation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation</title>
        <description>Image quality (anatomic details, motion artifacts, beam hardening and enhancement of pancreatic tissue and tumor were scored from 1 to 5, with 1 being very poor and 5 being excellent), CT number of pancreas and tumor, tumor-to-pancreas contrast, image noise and contrast-to-noise ration (CNR) were compared among contrast-enhanced (CE) 4DCT, CE 3DCT and 4DCT without contrast enhancement.</description>
        <time_frame>1 year</time_frame>
        <population>Image data of 10 patients (of the 12 patients who completed the study) was good for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CE 3DCT</title>
            <description>Contrast-enhanced 3DCT</description>
          </group>
          <group group_id="O2">
            <title>4DCT</title>
            <description>4DCT without contrast</description>
          </group>
          <group group_id="O3">
            <title>CE 4DCT</title>
            <description>Individually optimized contrast-enhanced 4DCT</description>
          </group>
        </group_list>
        <measure>
          <title>Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation</title>
          <description>Image quality (anatomic details, motion artifacts, beam hardening and enhancement of pancreatic tissue and tumor were scored from 1 to 5, with 1 being very poor and 5 being excellent), CT number of pancreas and tumor, tumor-to-pancreas contrast, image noise and contrast-to-noise ration (CNR) were compared among contrast-enhanced (CE) 4DCT, CE 3DCT and 4DCT without contrast enhancement.</description>
          <population>Image data of 10 patients (of the 12 patients who completed the study) was good for analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anatomic details</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.8"/>
                    <measurement group_id="O2" value="2.5" spread="0.6"/>
                    <measurement group_id="O3" value="3.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motion artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.0"/>
                    <measurement group_id="O2" value="3.4" spread="0.9"/>
                    <measurement group_id="O3" value="3.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beam hardening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.8"/>
                    <measurement group_id="O2" value="3.3" spread="0.9"/>
                    <measurement group_id="O3" value="3.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enhancement of pancreatic tissue and tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.0"/>
                    <measurement group_id="O2" value="1.7" spread="0.9"/>
                    <measurement group_id="O3" value="3.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation</title>
        <description>Image quality (anatomic details, motion artifacts, beam hardening and enhancement of pancreatic tissue and tumor were scored from 1 to 5, with 1 being very poor and 5 being excellent), CT number of pancreas and tumor, tumor-to-pancreas contrast, image noise and contrast-to-noise ration (CNR) were compared among contrast-enhanced (CE) 4DCT, CE 3DCT and 4DCT without contrast enhancement.</description>
        <time_frame>1 year</time_frame>
        <population>Image data of 10 patients (of the 12 patients who completed the study) was good for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CE 3DCT</title>
            <description>Contrast-enhanced 3DCT</description>
          </group>
          <group group_id="O2">
            <title>4DCT</title>
            <description>4DCT without contrast</description>
          </group>
          <group group_id="O3">
            <title>CE 4DCT</title>
            <description>Individually optimized contrast-enhanced 4DCT</description>
          </group>
        </group_list>
        <measure>
          <title>Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation</title>
          <description>Image quality (anatomic details, motion artifacts, beam hardening and enhancement of pancreatic tissue and tumor were scored from 1 to 5, with 1 being very poor and 5 being excellent), CT number of pancreas and tumor, tumor-to-pancreas contrast, image noise and contrast-to-noise ration (CNR) were compared among contrast-enhanced (CE) 4DCT, CE 3DCT and 4DCT without contrast enhancement.</description>
          <population>Image data of 10 patients (of the 12 patients who completed the study) was good for analysis.</population>
          <units>HU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pancreas CT number (HU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="12.3"/>
                    <measurement group_id="O2" value="44.6" spread="15.9"/>
                    <measurement group_id="O3" value="75.5" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor CT number (HU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" spread="9.2"/>
                    <measurement group_id="O2" value="58.9" spread="14.3"/>
                    <measurement group_id="O3" value="76.3" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor to pancreas contrast (HU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="20.7"/>
                    <measurement group_id="O2" value="9.2" spread="9.2"/>
                    <measurement group_id="O3" value="16.7" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noise (HU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.9"/>
                    <measurement group_id="O2" value="19.4" spread="5.8"/>
                    <measurement group_id="O3" value="22.1" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation</title>
        <description>Image quality (anatomic details, motion artifacts, beam hardening and enhancement of pancreatic tissue and tumor were scored from 1 to 5, with 1 being very poor and 5 being excellent), CT number of pancreas and tumor, tumor-to-pancreas contrast, image noise and contrast-to-noise ration (CNR) were compared among contrast-enhanced (CE) 4DCT, CE 3DCT and 4DCT without contrast enhancement.</description>
        <time_frame>1 year</time_frame>
        <population>Image data of 10 patients (of the 12 patients who completed the study) was good for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CE 3DCT</title>
            <description>Contrast-enhanced 3DCT</description>
          </group>
          <group group_id="O2">
            <title>4DCT</title>
            <description>4DCT without contrast</description>
          </group>
          <group group_id="O3">
            <title>CE 4DCT</title>
            <description>Individually optimized contrast-enhanced 4DCT</description>
          </group>
        </group_list>
        <measure>
          <title>Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation</title>
          <description>Image quality (anatomic details, motion artifacts, beam hardening and enhancement of pancreatic tissue and tumor were scored from 1 to 5, with 1 being very poor and 5 being excellent), CT number of pancreas and tumor, tumor-to-pancreas contrast, image noise and contrast-to-noise ration (CNR) were compared among contrast-enhanced (CE) 4DCT, CE 3DCT and 4DCT without contrast enhancement.</description>
          <population>Image data of 10 patients (of the 12 patients who completed the study) was good for analysis.</population>
          <units>contrast to noise ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.9"/>
                    <measurement group_id="O2" value="0.6" spread="0.7"/>
                    <measurement group_id="O3" value="0.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Enrolled Patients</title>
          <description>One death among enrolled patients, which was not directly related to this research.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Zhang, PhD</name_or_title>
      <organization>UMMC MSGCC</organization>
      <phone>(410)706-6510</phone>
      <email>hzhang@umm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

